Potent, selective human β3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore
摘要:
A series of compounds possessing an N-substituted indoline-5-sulfonamide pharmacophore was prepared and evaluated for their human beta(3) adrenergic receptor agonist activity. The SAR of a wide range of urea and heterocyclic substituents is discussed. 4-Octyl thiazole compound 8c was the most potent and selective compound in the series, with 2800-fold selectivity over beta(1) binding and 1400-fold selectivity over beta(2) binding (C) 1999 Elsevier Science Ltd. All rights reserved.
Potent, selective human β3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore
摘要:
A series of compounds possessing an N-substituted indoline-5-sulfonamide pharmacophore was prepared and evaluated for their human beta(3) adrenergic receptor agonist activity. The SAR of a wide range of urea and heterocyclic substituents is discussed. 4-Octyl thiazole compound 8c was the most potent and selective compound in the series, with 2800-fold selectivity over beta(1) binding and 1400-fold selectivity over beta(2) binding (C) 1999 Elsevier Science Ltd. All rights reserved.
[EN] PI3K-α INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PI3K-α ET PROCÉDÉ D'UTILISATION DE CEUX-CI
申请人:RELAY THERAPEUTICS INC
公开号:WO2021222556A1
公开(公告)日:2021-11-04
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-α enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-α signaling with the compounds and compositions of the disclosure.
Control of unwanted vegetation with N-carbamylindolines
申请人:Gulf Oil Corporation
公开号:US04428881A1
公开(公告)日:1984-01-31
New N-carbamylindolines which are useful in combating unwanted vegetation by both pre-emergent and post-emergent application are compounds having the structural formula ##STR1## in which R and R.sup.3 are hydrogen or methyl, R.sup.1 is hydrogen or N,N-dimethylsulfamyl, N,N-diethylsulfamyl, N-methoxy-N-methyl-sulfamyl, bromo or chloro, X is hydrogen or fluoro and R.sup.2 is hydrogen or dimethylsulfamyl, with the provision that at least one and no more than two substituents represented by R.sup.1, R.sup.2, and R.sup.3 and X are present.